The End of the Needle? A New Tech Aims to Upend the Peptide Market

TORONTO, ON – May 29, 2026 – By Michael Bennett

The burgeoning multi-billion-dollar peptide market, fueling everything from regenerative medicine to the viral weight-loss trend, has long been tethered to a significant drawback: the needle. Most of these powerful amino acid chains are too fragile to survive digestion, forcing users into a routine of injections and refrigerated storage. A Canadian technology firm, however, believes it has a solution that could fundamentally change how these therapies are delivered.

Mountain Valley MD (MVMD) has announced it has successfully formulated several high-profile peptides—including the regenerative compound BPC-157 and next-generation weight-loss candidate retatrutide—into a needle-free, sublingual tablet. The company’s patented Quicksome™ platform technology aims to turn inconvenient injections into a simple tablet that dissolves under the tongue. This development arrives at a pivotal moment, as U.S. regulators are poised to make decisions that could dramatically expand the legal market for compounded peptides, potentially creating a massive new opportunity for whichever delivery method proves most effective and accessible.

The Promise of a Post-Injection Era

A fundamental challenge in peptide therapy is getting the delicate molecules into the bloodstream intact. The stomach's harsh acidic environment and digestive enzymes quickly degrade them, rendering traditional oral pills ineffective. This is why injections have remained the gold standard.

MVMD’s Quicksome™ technology seeks to bypass this problem entirely. By formulating peptides into a rapid-dissolve tablet placed under the tongue, the drug is designed to be absorbed directly through the highly vascularized mucosal tissue and enter systemic circulation. This route avoids the gastrointestinal tract and the “first-pass” degradation in the liver, potentially offering a more efficient and patient-friendly alternative.

“Our focus is entirely on Quicksome™ as a differentiated delivery platform that we believe has the potential to move important molecules from needle-based administration and refrigerated logistics toward a more accessible sublingual format,” stated Dennis Hancock, President and CEO of MVMD, in a recent press release.

The company claims this needle-free format offers several key advantages: improved patient convenience and compliance, especially for those averse to needles; expanded distribution flexibility; and the potential elimination of the cold chain—the costly refrigerated handling required for many biological drugs. This last claim is supported by a previous two-year collaborative research agreement with the U.S. Food and Drug Administration (FDA). In that study, Quicksome™ technology demonstrated its ability to preserve a heat-sensitive polio vaccine component at 40 degrees Celsius (104°F) for five days, suggesting a robust capability to stabilize fragile biological molecules at room temperature.

A Shifting Regulatory Landscape

While the technology is compelling, the timing of MVMD’s announcement is what lends it significant weight. The regulatory environment surrounding compounded peptides in the United States is undergoing a seismic shift. In late 2023, the FDA placed numerous popular peptides, including BPC-157, on its Category 2 bulk substances list, severely restricting their use by compounding pharmacies due to safety and data concerns. This move pushed many users toward a risky and unregulated gray market.

However, following a policy reversal announced by the U.S. Secretary of Health and Human Services in February 2026, the FDA is now actively reconsidering this stance. The agency’s Pharmacy Compounding Advisory Committee (PCAC) has scheduled a crucial public meeting for July 23-24, 2026. On the agenda is the potential reclassification of seven peptides—including BPC-157, KPV, and TB-500—from the restrictive Category 2 back to Category 1. A return to Category 1 would permit licensed pharmacies to legally compound these substances with a physician's prescription, effectively reopening a regulated pathway for patient access.

While the committee's recommendations are non-binding, they guide the FDA's formal rulemaking process. A positive review could unlock a significant portion of the peptide market that has been dormant. This potential market expansion creates a powerful incentive for companies like MVMD, which are not developing the peptides themselves but are creating the enabling delivery technologies.

Strategy, Science, and Scrutiny

Mountain Valley MD’s strategy is not to become a pharmaceutical giant but to be the technology provider that makes peptide therapies easier to use. The company has reported completing initial Quicksome™ formulation work for a slate of commercially significant peptides: BPC-157, GHK-Cu, KPV, SNAP-8, and even retatrutide—Eli Lilly’s triple-agonist GLP-class drug currently in Phase III trials and projected to be a blockbuster. The company's goal is to license its platform to compounding pharmacies and other distributors rather than navigate the lengthy and expensive process of proprietary drug development.

However, the path from a press release to widespread market adoption is fraught with challenges. While the company's internal formulation work and the previous vaccine stability data are promising, independent, peer-reviewed scientific studies validating the bioavailability and efficacy of Quicksome™ for these specific, complex peptides are not yet publicly available. Experts in pharmaceutical delivery note that achieving consistent absorption of large molecules through the sublingual route is notoriously difficult. Success will hinge on MVMD's ability to prove its technology delivers a therapeutic dose as reliably as an injection.

The global peptide therapeutics market, valued at approximately $141 billion in 2025 and projected to more than double by 2033, represents an enormous prize. The explosive growth of GLP-1 agonists for weight loss, which generated nearly $46 billion in 2024, illustrates the public's appetite for effective peptide-based treatments. If MVMD’s Quicksome™ platform can deliver on its promise of making these and other emerging therapies needle-free and stable at room temperature, it could be positioned as a key enabler in one of modern medicine’s fastest-growing categories. The company is betting that in the new peptide gold rush, selling the picks and shovels will be a very lucrative business.